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TREATMENT SATISFACTION INSTRUMENTS FOR DIFFERENT 
PURPOSES DURING A PRODUCT’S LIFECYCLE—KEEPING THE END IN 
MIND
Rofail D1, Regnault A2, Taylor F1, Filonenko A3
1Mapi Values Ltd, Bollington, Cheshire, UK; 2Mapi Values, Lyon, France; 3Bayer Schering 
Pharma AG, Berlin, Germany
OBJECTIVES: There are three main parts during a product’s lifecycle when satisfac-
tion instruments are particularly useful. These are to aid: 1) getting the product to the 
market; 2) getting the market to the product; and 3) demonstrating value for health 
care practitioners during daily clinical practice. This study investigates whether the 
development and implementation of treatment satisfaction instruments during a prod-
uct’s lifecycle are informed by their purpose. METHODS: A literature review was 
performed between 2000 and 2010 using electronic databases (PUBMED, PsycINFO, 
and EMBASE) and keywords such as “satisfaction” and “medication” or “drug” and 
“questionnaire.” Relevant articles were reviewed in detail to extract information 
regarding the satisfaction instrument used, its development and validation, and when 
the instrument was used during a product’s lifecycle. Additional information was 
collated including the type of studies the instruments were used in, clinical condition/
indication, type of data generated (e.g. descriptive), and whether satisfaction was 
associated with other endpoints. RESULTS: Of 875 abstracts, 105 articles were 
further considered. The review indicated similarities regarding the development and 
validation of satisfaction instruments, such as using patient input to derive the items 
and exploring classical measurement properties speciﬁ c to the target population. 
However, the speciﬁ cities of the implementation of treatment satisfaction during the 
three main stages of a product’s lifecycle were rarely considered. CONCLUSIONS: 
The development and implementation of treatment satisfaction instruments during a 
product’s lifecycle rarely consider the purpose. By “keeping the end in mind,” data 
from treatment satisfaction instruments can help three key parts: 1) getting the product 
to the market thus helping to generate evidence as part of an overall value proposition; 
2) getting the market to the product; and 3) demonstrating the value to clinical prac-
tice. Furthermore, the development, validation and interpretation of scores from 
treatment satisfaction instruments should be sensitive to the intended purpose. 
CONCEPTUAL PAPERS & RESEARCH ON METHODS – Statistical Methods
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SYSTEMATIC REVIEW OF METHODS FOR META-ANALYSIS AND 
INDIRECT COMPARISON USED IN EXISTING SYSTEMATIC REVIEWS 
AND HTA REPORTS—RESULTS FROM THE FIRST PART OF EBAYESMET 
PROJECT
Walczak J1, Borowiack E1, Kowalska M1, Nikodem M2, Zapalska A1
1Arcana Institute, Cracow, Poland; 2CASPolska, Myslenice, Poland
OBJECTIVES: To collect information serve as a background for further activities of 
the eBayesMet project. To perform assessment of the frequency of use the particular 
statistical methods for meta-analyses and indirect comparisons in existing systematic 
reviews and HTA reports. METHODS: Database of Reviews of Effectiveness (DARE) 
was searched for relevant reviews published between January 2009 and March 2010. 
RESULTS: The majority of meta-analyses were prepared by using direct statistical 
methods (97%). The most popular expression about ﬁ xed model was that ﬁ xed effect 
model with the Mantel-Haenszel was used (36%). In case of random model, informa-
tion that method DerSimonian Laird was selected (38%) was used most often. Meta-
analyses were prepared mostly based on randomized controlled trials (87%) and in 
3% only on observational studies. In meta-analyses based on RCTs in 42% of cases 
authors mentioned that to make strong conclusion more studies were needed. Employ-
ing Bayesian methods was generally very rare. For indirect comparisons six methods 
were recognized and the most common type was MTC Bayesian Model (53%). 
Observational studies were not included in any identiﬁ ed analysis. In 40% of the 
review information indicating the need for additional studies was contained. CON-
CLUSIONS: Our systematic reviews demonstrates a wide range of approaches and 
methods for conducting meta-analyses and indirect comparison used in current prac-
tice. The most popular approach for indirect comparison is Bayesian included network 
and MTC (over 65%). However performed analysis indicated that Bayesian approach 
is still marginal methods for performing direct comparison based on head to head 
studies. Bayesian models have essential advantage: some additional data can be 
included (as a prior distribution). This extra information can be for instance data from 
observational studies. However it should be emphasized, that in the analyzed random 
sample of systematic reviews studies other than RCT were included in only 13%.
PMC56
IMPROVED SURVIVAL CURVE FITS TO SUMMARY DATA FOR 
ECONOMIC EVALUATIONS
Hoyle MW
University of Exeter, Exeter, UK
OBJECTIVES: Estimates of mean cost and quality-adjusted-life-years are central to 
the cost-effectiveness analysis of health technologies. They are often calculated from 
curve ﬁ ts to overall survival and time on treatment, ideally by the method of maximum 
likelihood applied to individual patient data. However, such data is often not avail-
able. Instead, curves are commonly ﬁ t to summary Kaplan-Meier estimators, either 
by regression of the transformed estimator or by minimizing the sums of squares of 
differences between actual and ﬁ tted values. However, the tail of the estimator is often 
uncertain due to small numbers of patients at risk, and the curve ﬁ ts do not yield 
estimates of the true uncertainty in survival times, which is a very important compo-
nent of overall uncertainty in cost-effectiveness. Here, I describe a new, more accurate 
method of ﬁ tting survival curves to summary survival data. METHODS: First, I 
estimate the underlying individual patient data from the Kaplan-Meier estimator, 
numbers of patients at risk and from other published trial-related information. The 
ﬁ tted curve is then estimated by maximum likelihood given the estimated underlying 
individual patient data. RESULTS: Simulation applied to individual patient data 
shows that the method tends to give a more accurate curve ﬁ t than the traditional 
methods of ﬁ tting to the Kaplan-Meier estimator. Furthermore, the curve ﬁ t is often 
very similar to that derived by ﬁ tting to the underlying individual patient data by 
maximum likelihood. The method naturally yields accurate estimates of the uncer-
tainty in survival times. When applied to economic evaluations submitted to NICE, 
the method often yields substantially improved estimates of cost-effectiveness com-
pared to estimates based on ﬁ tting survival curves in the traditional manner. This 
highlights the sensitivity of many cost-effectiveness analyses to curve ﬁ ts. CONCLU-
SIONS: When only summary survival data is available, I recommend the method for 
cost-effectiveness analysis.
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BIAS IS WORSE THAN NOISE: HANDLING MISSING DATA FOR 
CONFOUNDERS IN OBSERVATIONAL STUDIES
Elkin EP, Exuzides AK, Pasta DJ, Miller DP
ICON Clinical Research, San Francisco, CA, USA
OBJECTIVES: Outcomes research often employs observational designs (e.g., disease 
registries, administrative health care data sets, chart reviews). Researchers using obser-
vational data may ﬁ nd various amounts of missing data for confounders when analyz-
ing the association between an exposure (such as treatment use) and an outcome (such 
as an adverse event). This abstract examines the case when a potentially important 
confounding variable has a large amount of missing data and compares the analytic 
methods that may be used in this situation. METHODS: Strategies for handling 
missing confounder information include: (1) ignore confounders with lots of missing 
values; (2) exclude cases that are missing a confounder value; (3) impute a value for 
the confounder; (4) include missing as a separate category in the analysis. Data from 
a disease registry were used as the basis for simulations to compare the odds ratio for 
risk of death in patients who received a treatment compared to those without treat-
ment. Both a clinical measurement and a subjective physician assessment are known 
to confound the relationship between treatment and death. RESULTS: The most 
problematic pattern of missing data was informative missing data. In one simulation, 
the clinical measurement was a strong predictor of death; however, it was dispropor-
tionately missing in patients who had died. The physician assessment predicted death 
strongly among patients missing the clinical measurement, but only weakly in patients 
not missing the clinical data. Different approaches to the missing confounder data 
either exacerbated or ameliorated the problem. CONCLUSIONS: Excluding cases can 
create misleading results due to selection bias. Combining all missing values into a 
separate category can create data “noise” (i.e., classiﬁ cation error); however, this may 
be the most transparent strategy and least likely to bias results. It is important to 
include all cases and all potential confounders in the analysis of outcomes research 
studies.
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SYSTEMATIC REVIEW OF STATISTICAL METHODS OF META-ANALYSIS 
AND INDIRECT COMPARISON POTENTIALLY AVAILABLE TO USE IN 
SYSTEMATIC REVIEWS—RESULTS FROM THE FIRST PART OF 
EBAYESMET PROJECT
Walczak J1, Nikodem M2, Siedmiogrodzki K2, Zapalska A1, Borowiack E1
1Arcana Institute, Cracow, Poland; 2CASPolska, Myslenice, Poland
OBJECTIVES: To collect information serve as a background for further activities of 
the eBayesMet project. To identify statistical methods and approaches for performing 
meta-analyses and indirect comparisons. To describe limitations and mathematical 
background, to discuss advantages and disadvantages of identiﬁ ed methods. 
METHODS: Databases such as MathSciNet, Medline and Cochrane Methodology 
Group resources, textbooks, guidelines for preparing systematic reviews were 
searched. We focused on papers with strictly mathematical descriptions of presented 
methods. RESULTS: Eleven main statistical methods were identiﬁ ed. There were six 
methods of meta-analysis (Inverse Variance, Mantel-Haenszel, DerSimonian-Laird, 
Peto, Bayesian and Generalized Linear Mixed Models for direct comparison), and ﬁ ve 
methods of indirect and mixed comparison (Bûcher, Minimal Squares, Lumley, Bayes-
ian Mixed Treatment Comparison and Generalized Linear Mixed Models for indirect 
comparison). Moreover, there are different variants of some of these methods. For 
any type of analysis (direct, indirect, network, ﬁ xed, random, etc.) and any given data, 
there is an adequate version of Bayesian method for performing estimation. We found 
the Bayesian approach to be generally the most ﬂ exible.Analysis of precision and 
credibility of all identiﬁ ed statistical methods of meta-analysis and indirect comparison 
will be prepared in the next part of eBayesMet project. CONCLUSIONS: There are 
several statistical methods for performing proper data analysis in any model. The 
problem is with choosing optimal one for the given data set. On the other hand, all 
methods are less reliable and accurate for samples of data, especially for small (or 
zero) number of events in one or both arms. There is variety of statistical methods 
combining direct and indirect evidence, from which the most ﬂ exible is Mixed 
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Treatment Comparison using the Bayesian approach. Nevertheless, for each of these 
methods there are speciﬁ c assumptions which have to be satisﬁ ed in order to obtain 
correct estimation. 
CONCEPTUAL PAPERS & RESEARCH ON METHODS – Study Design
PMC60
INCLUSION OF CONFERENCE ABSTRACT DATA IN SYSTEMATIC 
REVIEWS OF PHARMACOLOGIC INTERVENTIONS IN DIFFERENT 
DISEASE AREAS
Zhang Y
Heron Evidence Development Ltd, Luton, England, UK
OBJECTIVES: Conference searching is a common part of systematic review methodol-
ogy, this study investigates what proportion of study/trial data included in systematic 
reviews of pharmacologic interventions is derived solely from data published in confer-
ence abstracts, for 3 different disease areas. METHODS: The Cochrane Library of 
systematic reviews (SRs) was searched for SRs on pharmacologic interventions which 
state that they include conference abstracts in their Specialized Registers and include 
conference searching as part of the stated SR methods. Included studies lists of com-
pleted systematic reviews were reviewed and the total number of included studies and 
the number of studies for which data was obtained only from conference abstracts 
were extracted. In disease areas where a large number of SRs met the inclusion criteria, 
the 10 most recently published SRs were selected. The following disease groups were 
considered: psychological disease (depression and bipolar disorder), female cancers 
(breast cancer and ovarian cancer), and arthritis (osteoarthritis and rheumatoid arthri-
tis). RESULTS: 3/10, 9/10 and 4/10 SRs contained studies solely from conference 
abstracts, for psychological disease, female cancers and arthritis respectively. For psy-
chological disease 5% (5/226) of all studies included in 10 SRs came only from confer-
ence abstracts, for female cancers this was 14% (31/220) and for arthritis this was 14% 
(33/232). CONCLUSIONS: The proportion of studies from conference abstracts only 
included in SRs varies in the 3 examined disease areas. From these results, there is 
some evidence to suggest that the disease area of the review should inform the decision 
of whether to include conference searching as part of the protocol. To answer this 
question more conclusively, a more expansive review of SRs should be conducted 
covering a greater number of SRs and disease areas.
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MONITORING OF HEALTH ECONOMIC DATA IN CLINICAL TRIALS
Bharmal M, Viswanathan S, Gemmen E
Quintiles, Rockville, MD, USA
OBJECTIVES: Health care decision makers are increasingly requesting health eco-
nomic (HE) data, both to support product approval and for marketing purposes. 
Currently, there is limited information available to aid decisions surrounding the 
clinical monitoring of HE endpoints when they are collected as part of a clinical trial. 
It is necessary to understand the current level of monitoring activities surrounding HE 
data and evolve best practices for monitoring such data. METHODS: To better 
understand monitoring activities, a literature review was performed and qualitative 
in-depth interviews were conducted with six clinical research associates (CRA) who 
had experience collecting HE data as part of clinical trials in a range of therapy areas. 
The literature review and interviews focused on understanding current clinical trial 
monitoring practices, monitoring activities speciﬁ c to HE data, the challenges faced 
during monitoring and recommendations for the future. RESULTS: All CRAs inter-
viewed reported working either with patient-reported outcome (PRO) measures—
quality of life questionnaires, patient diaries—and/or health care resource utilization 
data, in different therapy areas. Data monitoring activities in clinical trials can include 
a number of speciﬁ c tasks ranging from full source data veriﬁ cation (SDV) to partial 
SDV to just checking for accuracy, legibility and completeness. The most common 
challenges in monitoring of HE data included incomplete questionnaires, misinterpre-
tation of questionnaire data by the sites, and difﬁ culty in SDV of health care resource 
utilization data by the CRA. Recommendations for the future included optimizing 
methods for documentation of health care resource utilization data, improving patient/
site training in PRO use, and selecting the type of PRO and mode of PRO administra-
tion based on the patient population being examined. CONCLUSIONS: Health eco-
nomic endpoints are increasingly being used in clinical trials, and CRAs are becoming 
familiar with PRO and health care resource utilization data. Monitoring activities for 
HE data vary by the study design and type of data collected. 
CARDIOVASCULAR DISORDERS – Clinical Outcomes Studies
PCV1
ESTIMATION OF STROKE-RELATED ADVERSE EVENTS, HEALTH CARE 
UTILITY AND COST OF PATIENTS WITH NON-VALVULAR ATRIAL 
FIBRILLATION
Wang L1, Baser O2
1STATinMED Research, Ann Arbor, MI, USA; 2STATinMED Research/University of Michigan, 
Ann Arbor, MI, USA
OBJECTIVES: To estimate mortality, health care utility and health care cost burden of 
patients who suffered a stroke during the 180 days after diagnosis of non-valvular atrial 
ﬁ brillation (NVAF) and compare it with patients who did not suffer a stroke. 
METHODS: Based on 2005–2007 U.S. Medicare advantage insurance claim ﬁ les, 
patients aged 65 years and older who had 2 or more primary diagnoses for NVAF within 
30 days of one another were selected. The 180-day follow-up event rates, health care 
facility use and health care cost for patients with a stroke and those without were 
compared. Risk adjustment was done by using the propensity score matching method 
with the ProbChoiceTM algorithm. RESULTS: Out of patients identiﬁ ed with NVAF (n 
= 18,575), 575 suffered a stroke during the 180 days after NVAF diagnosis. 94% (n = 
541) did not have stroke during the baseline period (180 days before NVAF diagnosis). 
Patients were not signiﬁ cantly different in terms of gender, region, and baseline comor-
bid conditions. After risk-adjustment for pre-speciﬁ ed covariates, mortality (7.14% vs. 
2.09% P < 0.0001), outpatient emergency room (ER) visits (79.97% vs. 46.34% P < 
0.0001), acute coronary syndrome (43 vs. 16/100 person years), transient ischemic 
attack (73 vs. 4 /100 person years), major bleeding (85 vs. 4 /100 person years) and 
myocardial infarction (32 vs. 9/100 person years) were all higher for patients who suf-
fered a stroke compared to those who did not. Besides inpatient cost ($24,116 vs. 
$20,828), risk-adjusted outpatient ER costs ($921 vs. $873) were also higher for stroke 
patients. Overall risk-adjusted difference in health care costs is signiﬁ cant ($33,430 vs. 
$16,375 P < 0.0001). CONCLUSIONS: Most of the adverse events analyzed were 
higher for patients who suffered a stroke after NVAF relative to patients who did not. 
Total health care utility and health care cost were also signiﬁ cantly increased.
PCV2
ESTIMATION OF ADVERSE EVENTS IN 3 MONTHS AFTER VENOUS 
THROMBOEMBOLISM EVENT FOR MEDICARE PATIENTS WHO 
UNDERWENT HIP FRACTURE SURGERY
Wang L1, Dysinger A1, Baser O2
1STATinMED Research, Ann Arbor, MI, USA; 2STATinMED Research/University of Michigan, 
Ann Arbor, MI, USA
OBJECTIVES: To estimate mortality, re-hospitalization and bleeding 180 days after 
a venous thromboembolism (VTE) event in patients following hip fracture surgery and 
to compare the outcomes with patients without VTE. METHODS: Based on 2004–
2006 national Medicare claims, all patients who underwent hip fracture surgery were 
identiﬁ ed. a total of 180 days follow-up event rates for patients who had a VTE event 
during their initial hospitalization were calculated. Events were compared between 
patients who suffered a VTE event and those that did not. Risk adjustment was done 
using propensity score matching (using the ProbChoiceTM algorithm) controlling for 
baseline demographic and clinical characteristics between patients with and without 
VTE. RESULTS: In patients who underwent hip fracture surgery (n = 77,743), 2.23% 
had post-operative VTE events during their initial hospitalization. Almost 72.96% (n 
= 1263) of these patients suffered deep vein thrombosis (DVT), 20.97% (n = 363) had 
a pulmonary embolism (PE), and 6.07% (n = 105) had both DVT and PE. After 
multivariate adjustment for pre-speciﬁ ed covariates, mortality was almost 50% higher 
for patients with VTE compared to those without VTE. Differences in mortality rate 
were more pronounced for PE patients, whom the event was associated with almost 
two-fold. The VTE group was more likely to be re-hospitalized in one year (odds ratio: 
1.18, p = 0.2720). Bleeding was 1.8 times higher (p = 0.0080). CONCLUSIONS: VTE 
events during initial hospitalization for hip fracture surgery increased patients’ mortal-
ity, re-hospitalization and bleeding compared to patients with no VTE events.
PCV3
COMPARISON OF MORTALITY, HEALTH CARE UTILITY AND COST OF 
PATIENTS WITH WARFARIN TREATMENT FOR NON-VALVULAR 
ATRIAL FIBRILLATION VERSUS PATIENTS WITH OTHER TREATMENT
Wang L1, Baser O2
1STATinMED Research, Ann Arbor, MI, USA; 2STATinMED Research/University of Michigan, 
Ann Arbor, MI, USA
OBJECTIVES: To estimate the economic and clinical burden of patients who used 
warfarin during the 180 days after diagnosis of non-valvular atrial ﬁ brillation (NVAF) 
and compare it with patients who did not use warfarin. METHODS: Based on 
2005–2007 U.S. Medicare advantage insurance claim ﬁ les, patients aged 65 years and 
older who have had 2 or more primary diagnoses for NVAF occurring within 30 days 
of one another were selected. The 180 days follow-up event rates, health care facility 
use and cost were compared. Risk adjustment was done by using the propensity score 
matching method with the ProbChoiceTM algorithm. RESULTS: In patients who 
identiﬁ ed with NVAF (n = 18,575) 12,186 used warfarin during the 180 days after 
NVAF diagnosis and 6,389 used other drugs or did not use any drugs. Patients were 
signiﬁ cantly different in terms of age, gender, comorbid conditions and baseline 
CHADS score. After risk-adjustment for pre-speciﬁ ed covariates, mortality (0.75% vs. 
2.26%), outpatient emergency room (ER) visits (48.79% vs. 53.30%), acute coronary 
syndrome (105 vs. 154 /100 person years), and myocardial infarction (61 vs. 112 /100 
person years) were all lower for patients who had warfarin with non-valvular atrial 
ﬁ brillation. Even though drug cost is higher for the warfarin group ($1,687 vs. 
$1,595), risk-adjusted outpatient ER costs ($756 vs. $861) were lower. Overall risk-
adjusted health care costs did not differ ($12,739 vs. $15,359). CONCLUSIONS: 
Most of the adverse events analyzed were lower for patients who had warfarin after 
non-valvular atrial ﬁ brillation relative to patients who did not. However, the economic 
burden of both groups of patients on the health care system was similar.
